Naturally Occurring CD4+CD25+ Regulatory T Cells Prevent but Do Not Improve Experimental Myasthenia Gravis
- 1 November 2010
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 185 (9) , 5656-5667
Abstract
In the current study, we investigated whether naturally occurring CD4+CD25+ T cells, separated by immunomagnetic anti-CD4 and anti-CD25 Abs from naive animals, are able to protect from experimental autoimmune myasthenia gravis (EAMG) and modify the progression of ongoing disease when administered to Torpedo californica acetylcholine receptor (AChR)-immunized Lewis rats. Even though CD4+CD25+ and CD4+CD25high T cell frequencies were similar in the spleens and lymph nodes of EAMG and healthy rats, we observed that CD4+CD25+ T cells isolated from the spleens of naive animals inhibited in vitro the Ag-induced proliferation of T cell lines specific to the self-peptide 97–116 of the anti-AChR subunit (R97-116), an immunodominant and myasthenogenic T cell epitope, whereas CD4+CD25+ T cells purified from the spleens of EAMG rats were less effective. CD4+CD25+ T cells from EAMG rats expressed less forkhead box transcription factor P3 but more CTLA-4 mRNA than healthy rats. Naive CD4+CD25+ T cells, obtained from naive rats and administered to T. californica AChR-immunized animals according to a preventive schedule of treatment, reduced the severity of EAMG, whereas their administration 4 wk postinduction of the disease, corresponding to the onset of clinical symptoms (therapeutic treatment), was not effective. We think that the exogenous administration of CD4+CD25+ naive T cells prevents the early events underlying the induction of EAMG, events linked to the T cell compartment (Ag recognition, epitope spreading, and T cell expansion), but fails to ameliorate ongoing EAMG, when the IgG-mediated complement attack to the AChR at the neuromuscular junction has already taken place.Keywords
This publication has 44 references indexed in Scilit:
- Expansion of regulatory T cells via IL‐2/anti‐IL‐2 mAb complexes suppresses experimental myastheniaEuropean Journal of Immunology, 2010
- Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?Immunology, 2008
- Foxp3+ regulatory T cells in the control of experimental CNS autoimmune diseaseJournal of Neuroimmunology, 2008
- Transplant Tolerance Associated With a Th1 Response and Not Broken by IL-4, IL-5, and TGF-β Blockade or Th1 Cytokine AdministrationTransplantation, 2007
- Myasthenia gravis: past, present, and futureJournal of Clinical Investigation, 2006
- Regulatory T cells: present facts and future hopesMedical Microbiology and Immunology, 2006
- Human CD4+CD25+ regulatory T cellsSeminars in Immunology, 2004
- Animal Models of Myasthenia GravisClinical Immunology, 2000
- Factors That Determine the Severity of Experimental Myasthenia GravisaaAnnals of the New York Academy of Sciences, 1998
- Immunochemical studies on acetylcholine receptor from Torpedo californicaImmunochemistry, 1977